Beta- Probe and Surgery in GEP NET: Evaluation of a New Probe
- Conditions
- Neuroendocrine Tumors
- Interventions
- Drug: Y90-DOTA-Tyr3-Octreotide
- Registration Number
- NCT04296149
- Lead Sponsor
- European Institute of Oncology
- Brief Summary
Radioguided surgery (RGS) with beta- radioisotopes is a novel approach focused on developing a new probe which, detecting electrons and operating with low background, provides a clearer delineation of the margins of lesions with low radiation exposition for surgeons.
To validate this procedure, ex vivo specimens of tumours expressing somatostatin receptors, as small-intestine neuroendocrine (SI-NET), will be tested
- Detailed Description
Small Intestinal neuroendocrine patients, with a positive Ga-68-DOTATOC PET/CT, will receive a small amount of beta- radiopharmaceutical (Y-90-DOTATOC), and then operated, as clinical indicated.
Tissue samples will be tested ex-vivo with a beta-probe prototype
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5
- SI NET patients, Ga-68-DOTATOC PET/CT positive, proposed for surgery
- negative PET/CT; pregnancy
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Y-90-DOTATOC Y90-DOTA-Tyr3-Octreotide Patients affected by Small Intestine neuroendocrine tumors
- Primary Outcome Measures
Name Time Method Evaluation of sensitivity of a beta- probe 2 years after receiving a small amount of radioactivity, patients will be operated and an evaluation of radioactivity on surgical specimens will be evaluated
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Chiara Maria Grana
🇮🇹Milano, Italy